(Q34521747)

2 August 2017

title

Mechanisms of action of ribavirin in antiviral therapies (English)

1 reference

2 August 2017

1 reference

R C Tam

1

1 reference

2 August 2017

J Y Lau

series ordinal

2

1 reference

2 August 2017

Z Hong

series ordinal

3

1 reference

2 August 2017

publication date

1 September 2001

1 reference

Antiviral Chemistry & Chemotherapy

2 August 2017

published in

1 reference

2 August 2017

volume

12

1 reference

2 August 2017

issue

5

1 reference

2 August 2017

page(s)

261-272

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Mechanism of La Crosse virus inhibition by ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Images in hepatology. Hepatic abscesses in a patient with yersiniosis and iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Analysis of a successful immune response against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

RNA virus error catastrophe: direct molecular test by using ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: failure in IL-2 production despite proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

The quasispecies of hepatitis C virus and the host immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Therapy of chronic hepatitis B with a 6-month course of ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

The broad spectrum antiviral agent ribavirin inhibits capping of mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Reactivation of chronic hepatitis C after withdrawal of immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Noncytolytic control of viral infections by the innate and adaptive immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Inhibition of vaccinia virus growth by the nucleoside analogue 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ribavirin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

The role of immune responses in the pathogenesis of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Ribavirin Induces Error-Prone Replication of GB Virus B in Primary Tamarin Hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Genetic heterogeneity of hepatitis C virus and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Lassa fever. Effective therapy with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

The expanding universe of T-cell subsets: Th1, Th2 and more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Studies on the mechanism of the antiviral activity of ribavirin against reovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: relationship with the response to interferon treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Capping of eucaryotic mRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Template/primer requirements and single nucleotide incorporation by hepatitis C virus nonstructural protein 5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

Interferon for non-A, non-B chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020101200501

10.1177/095632020101200501

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference